Guardant Health (GH) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Illumina (ILMN) has outperformed Guardant Health (GH) over the past year, gaining 177.0% versus a gain of 165.3%. Over five years, GH leads with a +65.7% price change compared with -32.9% for ILMN. Illumina is the larger company by market cap ($40.43 billion vs $22.59 billion), about 1.8 times the size, while Guardant Health is growing revenue faster (+32.9% vs -0.7%).
Illumina converts more of its revenue into profit, with a net margin of 19.6% versus -42.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GH | ILMN |
|---|---|---|
| Share price | $168.33 | $267.76 |
| Market cap | $22.59B | $40.43B |
| 1-day change | -1.38% | -2.11% |
| YTD return | +64.80% | +104.15% |
| 1-year return | +165.34% | +176.95% |
| 5-year return | +65.68% | -32.85% |
| P/E ratio (TTM) | — | 49.96 |
| Forward P/E | — | 43.83 |
| EPS (TTM) | $-3.45 | $5.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $982.02M | $4.34B |
| Revenue growth (YoY) | +32.88% | -0.66% |
| Net income (latest FY) | $-416.28M | $850.00M |
| Gross margin | 64.46% | 66.08% |
| Operating margin | -44.53% | 18.58% |
| Net margin | -42.39% | 19.57% |
| 52-week high | $191.05 | $309.35 |
| 52-week low | $61.00 | $88.00 |
| Distance from 52-week high | -11.89% | -13.44% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +18.72% | -16.40% |
| Average volume | 2.01M | 2.66M |
| Shares outstanding | 134.20M | 151.00M |
| Employees | 2,490 | 8,600 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed GH by 11.6 percentage points over the past year.
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
- Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs -0.66%).
About Guardant Health
GH stock →Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Health Care · Medical Specialities · 2,490 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
GH vs ILMN FAQ
Which is bigger, Guardant Health or Illumina?
Illumina (ILMN) is larger, with a market capitalization of $40.43B compared with $22.59B for Guardant Health (GH).
Which stock has performed better over the past year, GH or ILMN?
ILMN returned +176.95% over the past 12 months, compared with +165.34% for GH (price return, excluding dividends). Past performance does not predict future results.
Are Guardant Health and Illumina in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.